Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  ProMIS Neurosciences, Inc.    PMN   CA74346M1095

PROMIS NEUROSCIENCES, INC.

(PMN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about PROMIS NEUROSCIENCES, INC.
02/03PROMIS NEUROSCIENCESá : Offers Perspectives on Recent Progress in the Alzheimer'..
AQ
02/02PROMIS NEUROSCIENCESá : Edging Up After Offering Perspectives on Recent Progress..
MT
02/02PROMIS NEUROSCIENCESá : Offers Perspectives on Recent Progress in the Alzheimer'..
PU
01/12PROMIS NEUROSCIENCESá : Details Strategic Priorities for 2021
MT
01/12ProMIS Neurosciences Announces Strategic Priorities for 2021
GL
2020PROMIS NEUROSCIENCESá : Year in review, looking forward to 2021
PU
2020PROMIS NEUROSCIENCESá : Completes offering of special warrants
AQ
2020PROMIS NEUROSCIENCESá : Completes Offering of Special Warrants
AQ
2020ProMIS Neurosciences Completes Offering of Special Warrants
GL
2020PROMIS NEUROSCIENCESá : Completes offering of special warrants
PU
2020PROMIS NEUROSCIENCESá : Announces Third Quarter 2020 Results
PU
2020PROMIS NEUROSCIENCESá : Announces Third Quarter 2020 Results
AQ
2020PROMIS NEUROSCIENCESá : Announces Third Quarter 2020 Results
AQ
2020ProMIS Neurosciences Announces Third Quarter 2020 Results
GL
2020PROMIS NEUROSCIENCESá : Falls to Near 52-Week Low After FDA Committee Concludes ..
MT
2020PROMIS NEUROSCIENCESá : offers comments on recent FDA Advisory Committee meeting..
PU
2020PROMIS NEUROSCIENCESá : offers comments on recent FDA Advisory Committee meeting..
AQ
2020PROMIS NEUROSCIENCESá : offers comments on recent FDA Advisory Committee meeting..
AQ
2020ProMIS Neurosciences offers comments on recent FDA Advisory Committee meeting..
GL
2020PROMIS NEUROSCIENCESá : Closes first tranche of private placement
PU
2020PROMIS NEUROSCIENCESá : Closes First Tranche of Private Placement
AQ
2020ProMIS Neurosciences Closes First Tranche of Private Placement
GL
2020PROMIS NEUROSCIENCESá : Dr. Neil Cashman CSO, to Speak at 2020 ALS ONE Research ..
AQ
2020PROMIS NEUROSCIENCESá : adds Dr. David Wishart to its Scientific Advisory Board
AQ
2020PROMIS NEUROSCIENCESá : rsquo; Dr. Neil Cashman CSO, to Speak at 2020 ALS ONE Re..
AQ
2020PROMIS NEUROSCIENCESá : rsquo; Dr. Neil Cashman CSO, to Speak at 2020 ALS ONE Re..
AQ
2020ProMIS Neurosciences' Dr. Neil Cashman CSO, to Speak at 2020 ALS ONE Research..
GL
2020PROMIS NEUROSCIENCESá : adds Dr. David Wishart to its Scientific Advisory Board
PU
2020PROMIS NEUROSCIENCESá : adds Dr. David Wishart to its Scientific Advisory Board
AQ
2020PROMIS NEUROSCIENCESá : adds Dr. David Wishart to its Scientific Advisory Board
AQ
2020ProMIS Neurosciences adds Dr. David Wishart to its Scientific Advisory Board
GL
2020PROMIS NEUROSCIENCESá : Announces up to $3 million private placement offering of..
AQ
2020PROMIS NEUROSCIENCESá : Announces up to $3 million private placement offering of..
PU
2020PROMIS NEUROSCIENCESá : Announces Up to $3 Million Private Placement Offering of..
AQ
2020ProMIS Neurosciences Announces Up to $3 Million Private Placement Offering of..
GL
2020PROMIS NEUROSCIENCES' PERSPECTIVE ON : is approval likely?
PU
2020PROMIS NEUROSCIENCESá : Offers its Perspective on the Likelihood of Regulatory A..
AQ
2020PROMIS NEUROSCIENCESá : Offers its Perspective on the Likelihood of Regulatory A..
AQ
2020ProMIS Neurosciences Offers its Perspective on the Likelihood of Regulatory A..
GL
2020PROMIS NEUROSCIENCESá : Neil Cashman to Speak at Protein Misfolding Drug Discove..
AQ
2020PROMIS NEUROSCIENCESá : rsquo; Neil Cashman to Speak at Protein Misfolding Drug ..
AQ
2020PROMIS NEUROSCIENCESá : rsquo; Neil Cashman to Speak at Protein Misfolding Drug ..
AQ
2020ProMIS Neurosciences' Neil Cashman to Speak at Protein Misfolding Drug Disco..
GL
2020PROMIS NEUROSCIENCESá : to develop multivalent vaccine for Alzheimer's disease
AQ
2020PROMIS NEUROSCIENCESá : to develop multivalent vaccine for Alzheimer's disease
PU
2020PROMIS NEUROSCIENCESá : to develop multivalent vaccine for Alzheimer's disease
AQ
2020PROMIS NEUROSCIENCESá : to develop multivalent vaccine for Alzheimer's disease
AQ
2020ProMIS Neurosciences to develop multivalent vaccine for Alzheimer's disease
GL
2020PROMIS NEUROSCIENCESá : to Participate in H.C. Wainwright & Co. 22nd Annual Inve..
AQ
2020PROMIS NEUROSCIENCESá : to Participate in H.C. Wainwright & Co. 22nd Annual Inve..
AQ
2020ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 22nd Annual Inve..
GL
2020ProMIS Neurosciences Announces Second Quarter 2020 Results
GL
2020PROMIS NEUROSCIENCESá : CEO memorandum to ProMIS shareholders, August 11, 2020
PU
2020ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders
GL
2020PROMIS NEUROSCIENCESá : and BC Neuroimmunology announce revenue-sharing joint ve..
AQ
2020ProMIS Neurosciences and BC Neuroimmunology announce revenue-sharing joint ve..
GL
2020ProMIS Neurosciences announces adjournment and change of location of annual m..
GL
2020ProMIS Neurosciences and collaborator BC Neuroimmunology announce significant..
GL
2020ProMIS Neurosciences and collaborative team receive Supercluster Award suppor..
GL
2020PROMIS NEUROSCIENCESá : Chairman's Update details new programs from expanded use..
AQ
2020PROMIS NEUROSCIENCESá : and BC Neuroimmunology expand collaboration to develop a..
AQ
2020PROMIS NEUROSCIENCESá : Chairman's Memorandum, May 20, 2020
PU
2020ProMIS Neurosciences Chairman's Update details new programs from expanded use..
GL
2020ProMIS Neurosciences and BC Neuroimmunology expand collaboration to develop a..
GL
2020ProMIS Neurosciences Announces First Quarter 2020 Results
GL
2020ProMIS Neurosciences identifies multiple novel targets on SARS CoV-2 for deve..
GL
2020ProMIS Neurosciences develops novel antagonists for RACK1, a protein involved..
GL
2020ProMIS Neurosciences creates novel intrabodies for ALS, frontotemporal dement..
GL
2020PROMIS NEUROSCIENCESá : commends Biogen for clarifying aducanumab regulatory fil..
AQ
2020ProMIS Neurosciences announces collaboration to develop serological test to a..
GL
2020PROMIS NEUROSCIENCESá : Journal of the American Academy of Neurology Publishes P..
AQ
2020PROMIS NEUROSCIENCESá : Journal of the American Academy of Neurology Publishes P..
AQ
2020Journal of the American Academy of Neurology Publishes ProMIS Neurosciences' ..
GL
2020ProMIS Neurosciences to Present Data and Moderate Session at AAIC 2020
GL
2020PROMIS NEUROSCIENCESá : Announces approval for warrant repricing
AQ
1  2  3  4Next
Upcoming event on PROMIS NEUROSCIENCES, INC.